Skip to main content

Rosetta Accepting FNA Samples for Analysis with miRNA Lung Cancer Diagnostic

Premium

Rosetta Genomics this week announced that it has begun to accept fine-needle aspirate cell block samples for analysis using its miRview Squamous test, which uses microRNA signatures to differentiate squamous from non-squamous non-small-cell lung cancer.

"FNA is a less invasive method to obtain tumor cells compared with tumor resections or biopsies … [enabling] patients and physicians to benefit from a highly accurate diagnostic assay without having to undergo a more invasive procedure," the company said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.